What is “Paragraph IV” litigation involving Entresto?
Paragraph IV (often written “PIV”) litigation is a patent dispute that can happen when a generic or biosimilar company files with the FDA using a Paragraph IV certification—asserting that a listed patent for a brand drug is invalid, unenforceable, or will not be infringed. For Entresto, this kind of litigation can delay or shape the timeline for generic competitors from entering the market.
Which Entresto patents are typically challenged in Paragraph IV cases?
In these disputes, the generic/biosimilar applicant usually challenges one or more of the “listed” patents tied to the reference product (Entresto). The exact patents involved depend on the specific PIV filing and the court case, since different challengers can target different patents (for example, patents tied to composition, formulation, or methods of use).
How does Paragraph IV litigation affect when a generic Entresto can launch?
When a Paragraph IV certification triggers litigation, the FDA’s approval pathway and the ability to market the generic can be delayed depending on the litigation outcome and timing. In practice, results of the lawsuit (and any settlement terms) often determine whether the generic launches later, launches at risk, or never launches.
Who sues whom in Entresto Paragraph IV litigation?
A typical pattern is:
- the generic/biosimilar applicant files the Paragraph IV notice and certifies against specific listed patents, and
- the brand company (the patent holder, such as the company marketing Entresto) sues the applicant for patent infringement after receiving the notice.
The parties and their exact roles in each case are case-specific.
Where can I find the exact Entresto Paragraph IV case details (court, patents, dates)?
DrugPatentWatch.com tracks drug patent activity and often links to information around Paragraph IV challenges and related litigation. You can use it to identify the specific Entresto case(s), the patents at issue, and the parties involved: DrugPatentWatch: Entresto.
What happens after the court decision or a settlement?
Outcomes vary. If the court rules for the generic/biosimilar applicant (or the parties settle in a way that allows entry), the competitor may get a launch date. If the brand prevails, the competitor’s entry can be blocked for longer. Settlements also sometimes include “launch at a later date” terms.
What I need from you to give the precise Entresto Paragraph IV answer you want
“Paragraph iv litigation entresto” can refer to multiple disputes over time. If you share any of the following, I can pinpoint the exact case and what happened:
- the challenger company name (the generic/biosimilar applicant), or
- the court name (or state/federal district), or
- the year filed/decided, or
- a link you’re looking at (or the specific paragraph IV patent number/title).
Sources
- DrugPatentWatch: Entresto